Skip to main content
Erschienen in:

01.08.2011 | Leitthema

Lokal ablative nichtchirurgische Verfahren beim nichtkleinzelligen Bronchialkarzinom

verfasst von: PD Dr. M. Guckenberger, M. Flentje

Erschienen in: Die Onkologie | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die konventionelle Strahlentherapie war bis vor wenigen Jahren der anerkannte Goldstandard, wenn im Stadium I des nichtkleinzelligen Bronchialkarzinoms (NSCLC) eine operative Therapie aus internistischen Gründen nicht möglich war. In diesem Beitrag wird der Stellenwert von neuen, lokal ablativen Therapieoptionen zusammengefasst. Die körperstereotaktische Bestrahlung (SBRT) erzielt konsistent lokale Tumorkontrollraten von 90% und verbessert im Vergleich zur konventionellen Strahlentherapie das Gesamtüberleben. Auch beim alten Patienten und fortgeschrittener Lungenerkrankung ist die SBRT sicher und bietet einen kurativen Ansatz. Lokale Tumorkontrolle wird mittels Radiofrequenzablation nur in maximal 70% der Patienten erzielt, bei Tumoren >3 cm in weniger als 50%. Die SBRT wird daher als nichtchirurgische Therapie der Wahl angesehen.
Literatur
1.
Zurück zum Zitat Rowell NP, Williams CJ (2001) Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev (2):CD002935 Rowell NP, Williams CJ (2001) Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev (2):CD002935
2.
Zurück zum Zitat Crestanello JA, Allen MS, Jett JR et al (2004) Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. J Thorac Cardiovasc Surg 128(2):254–259PubMedCrossRef Crestanello JA, Allen MS, Jett JR et al (2004) Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. J Thorac Cardiovasc Surg 128(2):254–259PubMedCrossRef
3.
Zurück zum Zitat Meyers BF, Haddad F, Siegel BA et al (2006) Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg 131(4):822–829; discussion 822–829PubMedCrossRef Meyers BF, Haddad F, Siegel BA et al (2006) Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg 131(4):822–829; discussion 822–829PubMedCrossRef
4.
Zurück zum Zitat Stiles BM, Servais EL, Lee PC et al (2009) Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg 137(1):13–19PubMedCrossRef Stiles BM, Servais EL, Lee PC et al (2009) Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg 137(1):13–19PubMedCrossRef
5.
Zurück zum Zitat Belderbos J, Hope A, Kestin L et al (2010) Time Interval between staging FDG positron emission tomography (PET) and initiation of stereotactic lung radiotherapy (SBRT) impacts the risk of recurrence and metastasis in non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys, 78(3, Supplement 1):S33–S33 Belderbos J, Hope A, Kestin L et al (2010) Time Interval between staging FDG positron emission tomography (PET) and initiation of stereotactic lung radiotherapy (SBRT) impacts the risk of recurrence and metastasis in non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys, 78(3, Supplement 1):S33–S33
6.
Zurück zum Zitat Guckenberger M, Wulf J, Mueller G et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74(1):47–54PubMedCrossRef Guckenberger M, Wulf J, Mueller G et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74(1):47–54PubMedCrossRef
7.
Zurück zum Zitat Bral S, Gevaert T, Linthout N et al (2010) Prospective, Risk-Adapted Strategy of Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: Results of a Phase II Trial. Int J Radiat Oncol Biol Phys Bral S, Gevaert T, Linthout N et al (2010) Prospective, Risk-Adapted Strategy of Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: Results of a Phase II Trial. Int J Radiat Oncol Biol Phys
8.
Zurück zum Zitat Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28(6):928–935PubMedCrossRef Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28(6):928–935PubMedCrossRef
9.
Zurück zum Zitat Onishi H, Shirato H, Nagata Y et al (2010) Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery? Int J Radiat Oncol Biol Phys [Epub] Onishi H, Shirato H, Nagata Y et al (2010) Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery? Int J Radiat Oncol Biol Phys [Epub]
10.
Zurück zum Zitat Palma D, Visser O, Lagerwaard FJ et al (2010) Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non-Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis. J Clin Oncol 28(35):5152–5159CrossRef Palma D, Visser O, Lagerwaard FJ et al (2010) Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non-Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis. J Clin Oncol 28(35):5152–5159CrossRef
11.
Zurück zum Zitat Haasbeek C, Palma D, Lagerwaard FJ et al (2010) Stereotactic Body Radiotherapy (SBRT) Outcomes in Stage I Lung Cancer Patients With Severe Chronic Obstructive Pulmonary Disease (GOLD III–IV). Int J Radiat Oncol Biol Phys 78(3, Suppl 1):S183–S183 Haasbeek C, Palma D, Lagerwaard FJ et al (2010) Stereotactic Body Radiotherapy (SBRT) Outcomes in Stage I Lung Cancer Patients With Severe Chronic Obstructive Pulmonary Disease (GOLD III–IV). Int J Radiat Oncol Biol Phys 78(3, Suppl 1):S183–S183
12.
Zurück zum Zitat Onishi H, Marino K, Terahara A et al (2009) Case Series Study of 26 Patients Who Developed Fatal Radiation Pneumonitis (RP) after Stereotactic Body Radiotherapy for Lung Cancer. Int J Radiat Oncol Biol Phys 75(3, Suppl 1):S62–S62 Onishi H, Marino K, Terahara A et al (2009) Case Series Study of 26 Patients Who Developed Fatal Radiation Pneumonitis (RP) after Stereotactic Body Radiotherapy for Lung Cancer. Int J Radiat Oncol Biol Phys 75(3, Suppl 1):S62–S62
13.
Zurück zum Zitat Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24(30):4833–4839PubMedCrossRef Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24(30):4833–4839PubMedCrossRef
14.
Zurück zum Zitat Stephans KL, Djemil T, Reddy CA et al (2009) Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 4(7):838–844PubMedCrossRef Stephans KL, Djemil T, Reddy CA et al (2009) Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 4(7):838–844PubMedCrossRef
15.
Zurück zum Zitat Voort van Zyp NC van der, Prevost JB, Holt B van der et al (2010) Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 77(1):31–37CrossRef Voort van Zyp NC van der, Prevost JB, Holt B van der et al (2010) Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 77(1):31–37CrossRef
16.
Zurück zum Zitat Ambrogi MC, Lucchi M, Dini P et al (2006) Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic. Surgery 30(1):177–183 Ambrogi MC, Lucchi M, Dini P et al (2006) Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic. Surgery 30(1):177–183
17.
Zurück zum Zitat Simon CJ, Dupuy DE, DiPetrillo TA et al (2007) Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 243(1):268–275PubMedCrossRef Simon CJ, Dupuy DE, DiPetrillo TA et al (2007) Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology 243(1):268–275PubMedCrossRef
18.
Zurück zum Zitat Lanuti M, Sharma A, Digumarthy SR et al (2009) Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 137(1):160–166PubMedCrossRef Lanuti M, Sharma A, Digumarthy SR et al (2009) Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 137(1):160–166PubMedCrossRef
19.
Zurück zum Zitat Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE (2010) Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology 254(1):301–307PubMed Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE (2010) Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology 254(1):301–307PubMed
20.
Zurück zum Zitat Schneider T, Reuss D, Warth A et al (2011) The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms – results of an ablate and resect study. Eur J Cardiothorac Surg 39(6):968-973PubMedCrossRef Schneider T, Reuss D, Warth A et al (2011) The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms – results of an ablate and resect study. Eur J Cardiothorac Surg 39(6):968-973PubMedCrossRef
21.
Zurück zum Zitat Zemlyak A, Moore WH, Bilfinger TV (2010) Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. J Am Coll Surg 211(1):68–72PubMedCrossRef Zemlyak A, Moore WH, Bilfinger TV (2010) Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. J Am Coll Surg 211(1):68–72PubMedCrossRef
22.
Zurück zum Zitat Lencioni R, Crocetti L, Cioni R et al (2008) Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 9(7):621–628PubMedCrossRef Lencioni R, Crocetti L, Cioni R et al (2008) Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 9(7):621–628PubMedCrossRef
23.
Zurück zum Zitat Nagata Y, Takayama K, Matsuo Y et al (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63(5):1427–1431PubMedCrossRef Nagata Y, Takayama K, Matsuo Y et al (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63(5):1427–1431PubMedCrossRef
24.
Zurück zum Zitat Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27(20):3290–3296PubMedCrossRef Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27(20):3290–3296PubMedCrossRef
25.
Zurück zum Zitat Fakiris AJ, McGarry RC, Yiannoutsos CT et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75(3):677–682PubMedCrossRef Fakiris AJ, McGarry RC, Yiannoutsos CT et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75(3):677–682PubMedCrossRef
26.
Zurück zum Zitat Ricardi U, Filippi AR, Guarneri A et al (2010) Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 68(1):72–77PubMedCrossRef Ricardi U, Filippi AR, Guarneri A et al (2010) Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 68(1):72–77PubMedCrossRef
27.
Zurück zum Zitat Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070–1076PubMedCrossRef Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070–1076PubMedCrossRef
28.
Zurück zum Zitat Lagerwaard FJ, Haasbeek CJ, Smit EF et al (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70(3):685–692PubMedCrossRef Lagerwaard FJ, Haasbeek CJ, Smit EF et al (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70(3):685–692PubMedCrossRef
29.
Zurück zum Zitat Grills IS, Hope AJ, Guckenberger M et al (2010) A multinational pooled analysis of 434 cases of stage I non-small cell lung cancer (NSCLC) treated with volumetrically image-guided (VIGRT) stereotactic lung radiotherapy (SBRT): Results from the elekta collaborative lung research group. J Clin Oncol (Meeting Abstracts) 28(suppl 15):7015–7015 Grills IS, Hope AJ, Guckenberger M et al (2010) A multinational pooled analysis of 434 cases of stage I non-small cell lung cancer (NSCLC) treated with volumetrically image-guided (VIGRT) stereotactic lung radiotherapy (SBRT): Results from the elekta collaborative lung research group. J Clin Oncol (Meeting Abstracts) 28(suppl 15):7015–7015
30.
Zurück zum Zitat Hiraki T, Gobara H, Iishi T et al (2007) Percutaneous radiofrequency ablation for clinical stage I non–small cell lung cancer: results in 20 nonsurgical candidates. J Thorac Cardiovasc Surg 134(5):1306–1312PubMedCrossRef Hiraki T, Gobara H, Iishi T et al (2007) Percutaneous radiofrequency ablation for clinical stage I non–small cell lung cancer: results in 20 nonsurgical candidates. J Thorac Cardiovasc Surg 134(5):1306–1312PubMedCrossRef
31.
Zurück zum Zitat Choe YH, Kim SR, Lee KS et al (2009) The use of PTC and RFA as treatment alternatives with low procedural morbidity in non-small cell lung cancer. Eur J Cancer 45(10):1773–1779PubMedCrossRef Choe YH, Kim SR, Lee KS et al (2009) The use of PTC and RFA as treatment alternatives with low procedural morbidity in non-small cell lung cancer. Eur J Cancer 45(10):1773–1779PubMedCrossRef
32.
Zurück zum Zitat Pennathur A, Abbas G, Gooding WE et al (2009) Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service. Ann Thorac Surg 88(5):1601–1606; discussion 1607–1608PubMedCrossRef Pennathur A, Abbas G, Gooding WE et al (2009) Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service. Ann Thorac Surg 88(5):1601–1606; discussion 1607–1608PubMedCrossRef
Metadaten
Titel
Lokal ablative nichtchirurgische Verfahren beim nichtkleinzelligen Bronchialkarzinom
verfasst von
PD Dr. M. Guckenberger
M. Flentje
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2011
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-011-2038-4

Weitere Artikel der Ausgabe 8/2011

Die Onkologie 8/2011 Zur Ausgabe

CME Weiterbildung · Zertifizierte Fortbildung

Gutartige Weichteiltumoren in der Orthopädie

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.